Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810557671> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2810557671 abstract "Objective: To describe multiple cases of neurologic complications, including myasthenia gravis, Guillian Barre syndrome, myositis, and hearing loss which occurred after exposure to immune checkpoint inhibitors. Background: Checkpoint inhibitors are increasingly used in the treatment of a variety of cancers, including renal cell carcinoma, melanoma, NSCLC, lymphoma, bladder cancer, and head and neck cancers. Immune checkpoint inhibitors are associated with T-cell reactions to self-antigens in addition to anti-cancer effects. Complications in multiple organ systems have been associated with this treatment, including skin, GI tract, kidney, liver, pancreas, and endocrine system abnormalities. Increasingly under-recognized are the neurologic side effects that occur with the use of immune checkpoint inhibitors, including the development of myasthenia gravis, myositis, as well as Guillain-Barre syndrome and hearing loss. Design/Methods: We report two cases of myasthenia gravis resulting after administration of PDL-1 inhibitors nivolumab and durvalumab, as well as CTLA-4 inhibitor tremelimumab with positive acetylcholine antibodies and positive decremental response on nerve conduction study. These drugs were used to treat a patient with squamous cell carcinoma of the parotid gland and a patient with non-small cell lung cancer. We also report a case of Guillian Barre syndrome resulting three weeks after administration of ipilimumab for the treatment of metastatic melanoma, and a case of myositis resulting after administration of atezolizumab, a PDL-1 inhibitor, which was given for the treatment of a urachal malignancy, with features of myasthenia gravis. Also reported is a case of hearing loss attributed to recent administration of pembrolizumab in a patient with metastatic melanoma. Results: Not Applicable Conclusions: Patients who have received immune checkpoint inhibitors for treatment of a primary malignancy are at risk to develop neurologic complications, including myasthenia gravis, Guillian Barre syndrome, and myositis. Patients who present with weakness, dysphagia, ptosis, and dysphonia after exposure to a checkpoint inhibitor should be screened fully for these conditions. Disclosure: Dr. Youssef has nothing to disclose. Dr. Woodman has nothing to disclose." @default.
- W2810557671 created "2018-07-10" @default.
- W2810557671 creator A5000069746 @default.
- W2810557671 creator A5034361979 @default.
- W2810557671 date "2018-04-10" @default.
- W2810557671 modified "2023-09-26" @default.
- W2810557671 title "Neurologic complications of immune checkpoint inhibitors in cancer patients (P4.162)" @default.
- W2810557671 hasPublicationYear "2018" @default.
- W2810557671 type Work @default.
- W2810557671 sameAs 2810557671 @default.
- W2810557671 citedByCount "0" @default.
- W2810557671 crossrefType "journal-article" @default.
- W2810557671 hasAuthorship W2810557671A5000069746 @default.
- W2810557671 hasAuthorship W2810557671A5034361979 @default.
- W2810557671 hasConcept C121608353 @default.
- W2810557671 hasConcept C126322002 @default.
- W2810557671 hasConcept C143998085 @default.
- W2810557671 hasConcept C203014093 @default.
- W2810557671 hasConcept C2777701055 @default.
- W2810557671 hasConcept C2777742743 @default.
- W2810557671 hasConcept C2778105408 @default.
- W2810557671 hasConcept C2779399171 @default.
- W2810557671 hasConcept C2780030458 @default.
- W2810557671 hasConcept C2780057760 @default.
- W2810557671 hasConcept C2781232998 @default.
- W2810557671 hasConcept C2781433595 @default.
- W2810557671 hasConcept C71924100 @default.
- W2810557671 hasConceptScore W2810557671C121608353 @default.
- W2810557671 hasConceptScore W2810557671C126322002 @default.
- W2810557671 hasConceptScore W2810557671C143998085 @default.
- W2810557671 hasConceptScore W2810557671C203014093 @default.
- W2810557671 hasConceptScore W2810557671C2777701055 @default.
- W2810557671 hasConceptScore W2810557671C2777742743 @default.
- W2810557671 hasConceptScore W2810557671C2778105408 @default.
- W2810557671 hasConceptScore W2810557671C2779399171 @default.
- W2810557671 hasConceptScore W2810557671C2780030458 @default.
- W2810557671 hasConceptScore W2810557671C2780057760 @default.
- W2810557671 hasConceptScore W2810557671C2781232998 @default.
- W2810557671 hasConceptScore W2810557671C2781433595 @default.
- W2810557671 hasConceptScore W2810557671C71924100 @default.
- W2810557671 hasLocation W28105576711 @default.
- W2810557671 hasOpenAccess W2810557671 @default.
- W2810557671 hasPrimaryLocation W28105576711 @default.
- W2810557671 hasRelatedWork W2116548718 @default.
- W2810557671 hasRelatedWork W2173856514 @default.
- W2810557671 hasRelatedWork W2546981544 @default.
- W2810557671 hasRelatedWork W2740283581 @default.
- W2810557671 hasRelatedWork W2754478142 @default.
- W2810557671 hasRelatedWork W2765527935 @default.
- W2810557671 hasRelatedWork W2773291959 @default.
- W2810557671 hasRelatedWork W2784065812 @default.
- W2810557671 hasRelatedWork W2803901052 @default.
- W2810557671 hasRelatedWork W2885240644 @default.
- W2810557671 hasRelatedWork W2902353061 @default.
- W2810557671 hasRelatedWork W2955338523 @default.
- W2810557671 hasRelatedWork W3086853676 @default.
- W2810557671 hasRelatedWork W3094885284 @default.
- W2810557671 hasRelatedWork W3101872502 @default.
- W2810557671 hasRelatedWork W3112605369 @default.
- W2810557671 hasRelatedWork W3133530288 @default.
- W2810557671 hasRelatedWork W3160702751 @default.
- W2810557671 hasRelatedWork W3164992864 @default.
- W2810557671 hasRelatedWork W3195067388 @default.
- W2810557671 hasVolume "90" @default.
- W2810557671 isParatext "false" @default.
- W2810557671 isRetracted "false" @default.
- W2810557671 magId "2810557671" @default.
- W2810557671 workType "article" @default.